New hope for tiniest babies: drug dose study aims to calm dangerous inflammation

NCT ID NCT07254000

First seen Jan 07, 2026 · Last updated May 13, 2026 · Updated 16 times

Summary

This study tests different doses and ways of giving the anti-inflammatory drug anakinra to very premature infants (born between 24 and 29 weeks). The goal is to find the safest and most effective dose to reduce inflammation and prevent lung problems. About 24 babies will take part, and researchers will monitor how the drug moves through their bodies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Monash Children's Hospital

    RECRUITING

    Clayton, Victoria, 3168, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Starship Children's Hospital

    NOT_YET_RECRUITING

    Grafton, Auckland, 1023, New Zealand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.